Approved For Marketing EXPANDED_ACCESS NCT03561194

Omegaven Protocol:Intermediate Size Patient Population

Sponsor: DHR Health Institute for Research and Development

Conditions Parenteral Nutrition Associated Liver Disease

Interventions Omegaven

Updated 6 times since 2018 Last updated: May 7, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03561194, this observational or N/A phase trial focuses on Parenteral Nutrition Associated Liver Disease and remains ongoing. Sponsored by DHR Health Institute for Research and Development, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Approved For Marketing
Jul 2024 — Sep 2024 [monthly]

Approved For Marketing
Jun 2021 — Jul 2024 [monthly]

Approved For Marketing
Jan 2021 — Jun 2021 [monthly]

Approved For Marketing
Sep 2018 — Jan 2021 [monthly]

Approved For Marketing

Status: Available → Approved For Marketing

▶ Show 1 earlier version

Jul 2018 — Sep 2018 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DHR Health Institute for Research and Development

Data source: DHR Health Institute for Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.